PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-853

For those thinking a surprise partnership with BP may be a near term catalyst, I ask you why?
If PAA has enough cash to get through the next trial, then one would assume no deal until results are in and our worth is increased.
Big question is whether we need one more soph raise in order to get to this point? I would prefer a discounted soph deal to a premature partnership.
Do we have a read on how much $$ would be saved by going the Healy route?
As for the SSP, if it is over subscribed I would hope that management take the extra $$ now for the above reason. If they scale back shareholders, then I expect management to scale their own allocations back to the same proportion (I doubt they will do this, hence my confidence that they will allow overs)